Blockade of Chronic Type I Interferon Signaling to Control Persistent LCMV Infection
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Type I interferons (IFN-I) are critical for antiviral immunity; however, chronic IFN-I signaling is associated with hyperimmune activation and disease progression in persistent infections. We demonstrated in mice that blockade of IFN-I signaling diminished chronic immune activation and immune suppression, restored lymphoid tissue architecture, and increased immune parameters associated with control of virus replication, ultimately facilitating clearance of the persistent infection. The accelerated control of persistent infection induced by blocking IFN-I signaling required CD4 T cells and was associated with enhanced IFN-γ production. Thus, we demonstrated that interfering with chronic IFN-I signaling during persistent infection redirects the immune environment to enable control of infection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, during viral infections, chronic type I and II IFN signaling can lead to immune suppression and a failure to clear viral infection.51-53”
From Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma (2021) · cites this paper as [52]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Restoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2006) · Nature · doi:10.1038/nature04444 · Cited by 3,986
PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression
Day, C. L., Kaufmann, D. E., Kiepiela, P., Brown, J. A., Moodley, E. S., Reddy, S., Mackey, E. W., Miller, J. D., Leslie, A. J., DePierres, C., et al. (2006) · Nature · doi:10.1038/nature05115 · Cited by 2,680
Functional Role of Type I and Type II Interferons in Antiviral Defense
Müller, U., Steinhoff, U., Reis, L. F. L., Hemmi, S., Pavlovic, J., Zinkernagel, R. M., & Aguet, M. (1994) · Science · doi:10.1126/science.8009221 · Cited by 2,453
Type I Interferon Inhibits Interleukin-1 Production and Inflammasome Activation
Guarda, G., Braun, M., Staehli, F., Tardivel, A., Mattmann, C., Förster, I., Farlik, M., Decker, T., Du Pasquier, R. A., Romero, P., et al. (2011) · Immunity · doi:10.1016/j.immuni.2011.02.006 · Cited by 933
Interleukin-10 determines viral clearance or persistence in vivo
Brooks, D. G., Trifilo, M. J., Edelmann, K. H., Teyton, L., McGavern, D. B., & Oldstone, M. B. A. (2006) · Nature Medicine · doi:10.1038/nm1492 · Cited by 923
Self-citationInterferon signaling and treatment outcome in chronic hepatitis C
Sarasin-Filipowicz, M., Oakeley, E. J., Duong, F. H. T., Christen, V., Terracciano, L., Filipowicz, W., & Heim, M. H. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707882105 · Cited by 642
Resolution of a chronic viral infection after interleukin-10 receptor blockade
Ejrnaes, M., Filippi, C. M., Martinic, M. M., Ling, E. M., Togher, L. M., Crotty, S., & von Herrath, M. G. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20061462 · Cited by 548
Jacquelin, B., Mayau, V., Targat, B., Liovat, A.-S., Kunkel, D., Petitjean, G., Dillies, M.-A., Roques, P., Butor, C., Silvestri, G., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci40093 · Cited by 481
Constitutive Type I Interferon Modulates Homeostatic Balance through Tonic Signaling
Gough, D. J., Messina, N. L., Clarke, C. J. P., Johnstone, R. W., & Levy, D. E. (2012) · Immunity · doi:10.1016/j.immuni.2012.01.011 · Cited by 470
Pathogenic Mechanisms of HIV Disease
Moir, S., Chun, T.-W., & Fauci, A. S. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130254 · Cited by 463
Research works printed but not linked: 2
- Brockman MA Blood 2009 114 346 19365081 PMC2714209 · DOI · Paper page
- 10.1089/jir.2012.0037 · DOI
Cited by
Items 501–600 of 713
Merritt, E., Londoño, M., Childs, K., Whitehouse, G. P., Kodela, E., Fueyo, A. S., & Martínez‐Llordella, M. (2020) · American Journal of Transplantation · doi:10.1111/ajt.16134 · Cited by 11
Macleod, B. L., Elsaesser, H. J., Snell, L. M., Dickson, R. J., Guo, M., Hezaveh, K., Xu, W., Kothari, A., McGaha, T. L., Guidos, C. J., et al. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20191473 · Cited by 12
“3 C), indicating that the ongoing IFN-I signaling was critical to constraining chronic virus replication and differentially affected virus control in the GIT compared with other peripheral organs (Teijaro et al., 2013; Wilson et al., 2013; Zhen et al., 2017).”
BackgroundSelf-citationKim, K.-S., Kim, D., Na, S., Jung, Y. S., Cho, S. J., Kim, J., Lee, I., Kim, Y.-H., Lee, C., Jeong, W., et al. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.2hi1219-762r · Cited by 12
The Yin–Yang arms of vaccines: disease-fighting power versus tissue-destructive inflammation
Tang, D.-C. C., & Nguyen, H. H. (2014) · Expert Review of Vaccines · doi:10.1586/14760584.2014.882775 · Cited by 11
“Among the many known pro- and anti-inflammatory cytokines, type I IFN plays balancing dual roles by controlling inflammation through diametrically opposed mechanisms [59,60].”
BackgroundDifferent antiviral effects of IFNα and IFNβ in an HBV mouse model
Zhou, Y., Li, S., Tang, Z., Xu, C., Huang, S., Wu, J., Dittmer, U., Dickow, J., Sutter, K., Lu, M., et al. (2016) · Immunobiology · doi:10.1016/j.imbio.2016.11.003 · Cited by 12
Transcriptional insights into the CD8+ T cell response in mono-HIV and HCV infection
Li, S.-Y., Zhang, Z., Jiang, Y., Fu, Y., & Shang, H. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02252-9 · Cited by 12
The pathogenic role of IFN-α in thyroiditis mouse models
Cheng, C., Fang, W.-F., Tang, K., & Lin, J. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.120172 · Cited by 10
Démoulins, T., Baron, M., Gauchat, D., Kettaf, N., Reed, S. J., Charpentier, T., Kalinke, U., Lamarre, A., Ahmed, R., Sékaly, R., et al. (2021) · Virology · doi:10.1016/j.virol.2021.12.007 · Cited by 10
The dawn of a new Era: mRNA vaccines in colorectal cancer immunotherapy
Song, J., Zhang, Y., Zhou, C., Zhan, J., Cheng, X., Huang, H., Mao, S., & Zong, Z. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112037 · Cited by 11
Ng, D., Maître, B., Cummings, D. T., Lin, A., Ward, L. A., Rahbar, R., Mossman, K. L., Ohashi, P. S., & Gommerman, J. L. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1501053 · Cited by 10
Aguilar‐Valenzuela, R., Carlsen, E. D., Liang, Y., Soong, L., & Sun, J. (2014) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12456 · Cited by 12
Pan, T., Cao, G., Tang, E., Zhao, Y., Penaloza‐MacMaster, P., Fang, Y. H., & Huang, J. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1105673 · Cited by 10
“However, during the late stages of chronic viral infection, IFN-I signaling shifts toward a pathogenic role by contributing to systemic inflammation (Teijaro et al., 2013; Wilson et al., 2013; Utay and Douek, 2016; Soper et al., 2017).”
BackgroundWang, G., Yoon, D., Nandi, A., Patel, K., Azar, T., Kim, J., Han, N. A., Nickie, A., Park, S., Wang, K., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.12.004 · Cited by 9
HIV and innate immunity – a genomics perspective
Rausell, A., McLaren, P. J., & Telenti, A. (2013) · F1000Prime Reports · doi:10.12703/p5-29 · Cited by 9
“What’s more, persistent production of interferon during chronic infection is thought to be deleterious [5-7].”
BackgroundMartini, H., Citro, A., Martire, C., d’Ettorre, G., Labbadia, G., Accapezzato, D., Piconese, S., Marzio, P. D., Cavallari, E. N., Calvo, L., et al. (2015) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiv460 · Cited by 9
“signaling [7, 8] in chronic HCV infection, we correlated the frequency of apoptotic epitope– or HCV-specific CD8 T cells with the expression of the following ISG transcripts in T cells from patients with chronic HCV infection and healthy donors: protein kinase R (PKR) – an IFN-inducible double-stranded”
BackgroundResultInfluentialClinical Trial Design for Immune-Based Therapy of Hepatitis B Virus
Gill, U. S., & Bertoletti, A. (2017) · Seminars in Liver Disease · doi:10.1055/s-0037-1600522 · Cited by 9
“Toll-free” pathways for production of type I interferons
Wang, L., & Ning, S. (2017) · AIMS Allergy and Immunology · doi:10.3934/allergy.2017.3.143 · Cited by 9
“At the early stage of infection, it has a potent antiviral activity; however, at late stages, a low level of prolonged IFN-I response facilitates the establishment and maintenance of persistent infection [17–22].”
Adamska, J. Z., Verma, R., Gupta, S., Hagan, T., Wimmers, F., Floyd, K. A., Li, Q., Valore, E. V., Wang, Y., Trisal, M., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112038 · Cited by 11
“20-23 Further, regulation of IFNAR1 signaling by transcription factor IRF2 has been demonstrated to be critical for homeostatic development of cDC2s in the spleen.”
Preston, S., Allison, C. C., Schaefer, J., Clow, W., Bader, S. M., Collard, S., Forsyth, W. O., Clark, M. P., Garnham, A. L., Suen, C. S. N. L. W., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05635-0 · Cited by 9
“Early blockade of IFN-I signalling does not alter the immediate number of LCMV-specific CD8 T cells but does augment enhanced control during the later stages of chronic infection [32, 33].”
BackgroundAgbayani, G., Wachholz, K., Murphy, S. P., Sad, S., & Krishnan, L. (2018) · American Journal of Reproductive Immunology · doi:10.1111/aji.13068 · Cited by 9
Type I interferons: One stone to concurrently kill two birds, viral infections and cancers
Kumar, A., Khani, A. T., & Swaminathan, S. (2021) · Current Research in Virological Science · doi:10.1016/j.crviro.2021.100014 · Cited by 9
Raja, R., Baral, S., & Dixit, N. M. (2018) · Immunological Reviews · doi:10.1111/imr.12689 · Cited by 9
Gadina, M., & O’Shea, J. J. (2024) · Science · doi:10.1126/science.adq1717 · Cited by 9
Feng, C., Li, Q., Yang, M., Chen, Y.-H., Zhang, M., Wang, H., & Li, X. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1702290 · Cited by 8
“Wilson et al. and Crow et al. reported that sustained type I interferon responses may contribute to the pathogenesis of chronic viral infections and autoimmune diseases (55, 56).”
Xu, H. C., Pandey, P., Ward, H., Gorzkiewicz, M., Abromavičiūtė, D., Tinz, C., Müller, L., Meyer, C., Pandyra, A. A., Yavas, A., et al. (2024) · The Journal of Immunology · doi:10.4049/jimmunol.2300637 · Cited by 8
Picat, M.-Q., Pellegrin, I., Bitard, J., Wittkop, L., Proust‐Lima, C., Liquet, B., Moreau, J., Bonnet, F., Blanco, P., Thiébaut, R., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0169164 · Cited by 8
Virus-associated activation of innate immunity induces rapid disruption of Peyer’s patches in mice
Heidegger, S. M., Anz, D., Stephan, N., Bohn, B., Herbst, T., Fendler, W. P., Suhartha, N., Sandholzer, N., Kobold, S., Hotz, C., et al. (2013) · Blood · doi:10.1182/blood-2013-01-479311 · Cited by 8
“During chronic virus infections, prolonged type I IFN release has been associatedwith hyperimmune activation, disruption of lymphoid tissue architecture, and disease progression.(41,42) It is thus possible that during chronic immune activation, prolonged changes in B-cell homing patterns may in fact hinder the control…”
BackgroundRuotsalainen, J. J., Lopez-Ramos, D., Rogava, M., Shridhar, N., Glodde, N., Gaffal, E., Hölzel, M., Bald, T., & Tüting, T. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1276 · Cited by 8
IFN-β, but not IFN-α, is Responsible for the Pro-Bacterial Effect of Type I Interferon
Shaabani, N., Vartabedian, V. F., Nguyen, N., Honke, N., Huang, Z., & Teijaro, J. R. (2021) · Cellular Physiology and Biochemistry · doi:10.33594/000000370 · Cited by 10
Teijaro, J. R. (2016) · European Journal of Immunology · doi:10.1002/eji.201546224 · Cited by 8
Parallels Between the Antiviral State and the Irradiated State
McGee, H. M., Marciscano, A. E. E., Campbell, A. M., Monjazeb, A. M., Kaech, S. M., & Teijaro, J. R. (2020) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaa190 · Cited by 13
“immune-regulatory molecules like PD-L1 and IL-10, promoting T-cell exhaustion and viral persistence (43,44).”
BackgroundZou, S., Du, Y., Huang, S., Chen, M., Yang, X., Li, S., Chen, Y., Han, M., Li, J., Yu, Q., et al. (2021) · Journal of Virology · doi:10.1128/jvi.00034-21 · Cited by 8
“IFN-I expression leads to hyperactivation of immunity and disease progression (11, 12).”
BackgroundInterfering with type I Interferon: A novel approach to purge persistent viral infection
Wilson, E. B., & Brooks, D. G. (2013) · Cell Cycle · doi:10.4161/cc.26175 · Cited by 8
Self-citationBeyond suppression: the paradox of JAK inhibitors as amplifiers of cancer immunotherapy
Žák, J., & Teijaro, J. R. (2026) · Nature reviews. Immunology · doi:10.1038/s41577-026-01266-6 · Cited by 8
“…I and type II interferons coordinately drive the development and suppressive function of dendritic cells, with IFNγ inducing monocyte-to-dendritic cell differentiation and type I interferons programming dendritic cells to potently suppress T cell responses, thereby promoting immune evasion 4,84 .”
InfluentialT Cell Exhaustion in Allergic Diseases and Allergen Immunotherapy: A Novel Biomarker?
Xu, Q., Li, L., & Zhu, R. (2025) · Current Allergy and Asthma Reports · doi:10.1007/s11882-025-01199-5 · Cited by 7
“Studies demonstrated that blocking IFN-I signaling reduced inhibitory molecule expression, and reversed or prevented T cell exhaustion [52, 53].”
Interleukin-4 modulates type I interferon to augment antitumor immunity
Newnes, H. V., Armitage, J. D., Buzzai, A. C., de Jong, E., Audsley, K. M., Barnes, S. A., Srinivasan, S., Serralha, M., Fear, V. S., Guo, B. B., et al. (2025) · Science Advances · doi:10.1126/sciadv.adt3618 · Cited by 7
Perpiñán, E., Pérez‐del‐Pulgar, S., Londoño, M., Mariñó, Z., Lens, S., Leonel, T., Bartrés, C., García‐López, M., Rodríguez‐Tajes, S., Forns, X., et al. (2020) · Journal of Viral Hepatitis · doi:10.1111/jvh.13370 · Cited by 8
Nguyen, N. Z. N., Tran, V. G., Baek, J. Y., Kim, Y., Youn, E. H., Na, S. W., Park, S. J., Seo, S., & Kwon, B. (2022) · The Journal of Immunology · doi:10.4049/jimmunol.2100495 · Cited by 7
Loo, C. P., Snyder, C. M., & Hill, A. B. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1600478 · Cited by 7
“secreting IL-10 (31, 32), In our experiments, it is possible that, in addition to impacting CD8 T cell numbers, type I IFN modulates”
BackgroundInfluentialStaupe, R. P., Vella, L. A., Manne, S., Giles, J. R., Meng, W., Herati, R. S., Khan, O., Wu, J. E., Baxter, A. E., Prak, E. T. L., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/849844 · Cited by 7
“Moreover, chronic viral infections in mice and humans can result in lymphoid tissue disruption and/or fibrosis (Mueller et al., 2007; Schacker et al., 2006; Wilson et al., 2013), perhaps impacting B cell responses.”
BackgroundChen, Y.-L., Yousif, A., Chen, C., Lowin, A. M., Saadey, A. A., Wang, S.-H., Jiang, S. S., Chen, Y., & Ghoneim, H. E. (2025) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-25-0047 · Cited by 6
Regulated necrosis at the crossroads of liver inflammation and cancer development
Vucur, M., Kondylis, V., Brož, P., & Luedde, T. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01147-8 · Cited by 7
Rodrigue‐Gervais, I. G., Rigsby, H., Jouan, L., Willems, B. E., & Lamarre, D. (2014) · PLoS ONE · doi:10.1371/journal.pone.0102605 · Cited by 6
Lang, E., Pozdeev, V. I., Shinde, P. V., Xu, H. C., Sundaram, B., Zhuang, Y., Poschmann, G., Huang, J., Stühler, K., Pandyra, A. A., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-30627-y · Cited by 6
Innate immunity and alpha/gammaherpesviruses: first impressions last a lifetime
Jondle, C. N., & Tarakanova, V. L. (2020) · Current Opinion in Virology · doi:10.1016/j.coviro.2020.07.002 · Cited by 6
“This observation and reports of proviral IFN function during chronic LCMV infection [21,22,77] raise an intriguing possibility that herpesviruses may usurp innate immune factors to facilitate aspects of chronic infection and regulate disease development.”
BackgroundHarker, J. A., Greene, T. T., Barnett, B. E., Bao, P., Dolgoter, A., & Zúñiga, E. I. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1221562 · Cited by 6
Autoimmunity-associated allele of tyrosine phosphatase gene PTPN22 enhances anti-viral immunity
Orozco, R. C., Marquardt, K., Pratumchai, I., Shaikh, A. F., Mowen, K. A., Domissy, A., Teijaro, J. R., & Sherman, L. A. (2024) · PLoS Pathogens · doi:10.1371/journal.ppat.1012095 · Cited by 8
Chung, Y. R., Awakoaiye, B., Dangi, T., Irani, N., Fourati, S., & Penaloza‐MacMaster, P. (2024) · Journal of Clinical Investigation · doi:10.1172/jci178945 · Cited by 6
“This MAR1-5A3 antibody binds to IFN-α / β receptor subunit 1 (clone IFNAR1) and blocks binding to IFN-α and IFN-β , abrogating the induction of ISGs in vivo (19, 20, 22, 38, 39).”
Contribution of Retrotransposable Elements to Aging
Kreiling, J. A., Jones, B. C., Wood, J. G., Cecco, M. D., Criscione, S. W., Neretti, N., Helfand, S. L., & Sedivy, J. M. (2017) · Springer eBooks · doi:10.1007/978-3-319-48344-3_13 · Cited by 7
Alves-Peixoto, P., Férez, M., Knudson, C. J., Stotesbury, C., Melo‐Silva, C. R., Wong, E. B., Correia‐Neves, M., & Sigal, L. J. (2019) · Journal of Virology · doi:10.1128/jvi.01831-19 · Cited by 6
Type I IFNs contribute to upregulation of PD-L1 during Chlamydia trachomatis infection
Reinhold-Larsson, N. V., & Starnbach, M. N. (2025) · Infection and Immunity · doi:10.1128/iai.00040-25 · Cited by 5
Senescent human fibroblasts have increased FasL expression and impair the tumor immune response
Cruz-Barrera, M., Dulong, J., Nehmo, G. M., Sonn, A., Moquin‐Beaudry, G., Benabdallah, B., Lê, O., & Beausejour, C. M. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1685269 · Cited by 5
“For example, prolonged exposure to SASP factors such as type 1 interferon and IL-6 were shown to downregulate immune cell functions (11 – 13) and to interfere with the tumor immune response mediated by T and NK cells (7 – 9).”
Plasmacytoid Dendritic Cell Lineage Adaptations During a Viral Infection
Chiale, C., Dallari, S., & Zúñiga, E. I. (2025) · Immunological Reviews · doi:10.1111/imr.70083 · Cited by 6
“While this IFN-I suppression is not absolute, since both IFN-I and interferon-stimulated genes can persistently be detected at low levels in tissues [156, 157], it nonetheless reflects a profound adaptation of the innate immune system occurring just days after viral infection.”
Guo-qing, Y., Chen, K., & Gu, X. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i40.5784 · Cited by 5
Meeting the Challenge of Controlling Viral Immunopathology
Berber, E., Mulik, S., & Rouse, B. T. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073935 · Cited by 5
“For example, two independent reports demonstrated that blocking type I interferon signaling in mice led to a favorable outcome during chronic LCMV infection, and this protective effect was dependent on CD4+ T cells [59,60].”
BackgroundCallon, D., Glenet, M., Lebreil, A.-L., Heng, L., Bouland, N., Fichel, C., Fornés, P., Andréoletti, L., & Berri, F. (2024) · PLoS Pathogens · doi:10.1371/journal.ppat.1012125 · Cited by 5
Shaabani, N., Žák, J., Johnson, J. L., Huang, Z., Nguyen, N., Lazar, D. C., Vartabedian, V. F., Honke, N., Jardine, J. G., Woehl, J. L., et al. (2024) · The Journal of Immunology · doi:10.4049/jimmunol.2400042 · Cited by 5
Type I IFN Exhaustion is a Host Defence Protecting Against Secondary Bacterial Infections
Furuya, Y., & Müllbacher, A. (2013) · Scandinavian Journal of Immunology · doi:10.1111/sji.12107 · Cited by 10
“With a few exceptions of chronic viral infections [6, 7] , most studies agree that IFN-I is protective against acute viral infections.”
BackgroundType I IFN Signaling Is Dispensable during Secondary Viral Infection
Hosking, M., Flynn, C. T., & Whitton, J. L. (2016) · PLoS Pathogens · doi:10.1371/journal.ppat.1005861 · Cited by 5
“Finally, T1IFN is also key to the development of immunopathology following influenza and SARS-CoV infection [30, 31] and during models of viral-induced hemorrhage [32, 33] .”
Excessive interferon-α signaling in autoimmunity alters glycosphingolipid processing in B cells
Tan, A. H., Sanny, A., Ng, S., Ho, Y. S., Basri, N. B., Lee, A., & Lam, K. (2017) · Journal of Autoimmunity · doi:10.1016/j.jaut.2017.11.004 · Cited by 5
Development of antiviral drugs against hepatitis B virus
Jiang, Y., Xia, Y., Zhao, K., & Xu, Z. (2019) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/tb-2019-0038 · Cited by 5
“然而 , 细胞因子如 IFNα, IFNβ 和 TNF 也 可以诱导慢性感染患者的免疫耐受 , 这可能会限制持 续的免疫控制 [119,120] .”
Polymorphisms of SOCS-1 Are Associated With a Rapid HIV Progression Rate
Hersberger, M., Schlaepfer, E., Bühler, M. M., Bochud, P., Vernazza, P., Marti-Jaun, J., Nemeth, J., Zwahlen, M., Schmidlin, K., Speck, R. F., et al. (2020) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000002319 · Cited by 5
Immunotherapy With Interferon α11, But Not Interferon Beta, Controls Persistent Retroviral Infection
Schwerdtfeger, M., Dickow, J., Schmitz, Y., Francois, S., Karakoese, Z., Malyshkina, A., Knuschke, T., Dittmer, U., & Sutter, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.809774 · Cited by 5
“Previous reports on chronic lymphocytic choriomeningitis virus (LCMV) infection of mice confirmed an antiviral role of type I IFNs during acute infection, but a rather detrimental role during chronic LCMV infection (22, 23).”
BackgroundQiu, J., Ye, D., Chen, X. E., Dangle, N. J., Yoshor, B., Zhang, T., Shao, Y., Nallamala, V. C., Wang, S., Ren, D., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.08.13.607862 · Cited by 5
An activating Stat1 mutant disrupts normal STAT4 innate lymphocyte programs during viral infection
Philips, R. L., Liao, Y.-C., Lau, C. M., Morrison, T. A., Jiang, K., Hutchinson, A., Shayne, J., Yao, C., Sun, J. C.-Y., Hickman, H. D., et al. (2025) · Science Immunology · doi:10.1126/sciimmunol.ado5986 · Cited by 6
Mosley, S. R., Lapa, N., Namdar, A., Catley, T. E., Meier‐Stephenson, F., Mowat, C., Gao, P., Sun, X., Meier‐Stephenson, V., Pyne, A. L. B., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117012 · Cited by 6
Cheng, L., Li, G., Luo, F., Bi, W., Lu, M., Liu, N., Zhao, Q., Han, R. J., Wang, H., Yang, H., et al. (2026) · Cellular and Molecular Immunology · doi:10.1038/s41423-026-01398-8 · Cited by 5
Pan-cancer single-cell atlases of mouse and human tumor-associated dendritic cells
Caro, A. A., Kancheva, D., Hadadi, É., Boeckx, B., Nolf, C. D., Bardet, P. M. R., Verstaen, K., Li, L., Oueslati, L., Figueras-Duch, N., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-73721-w · Cited by 6
The transcription factor IRF8 drives tumor-specific exhaustion in CD8+ T cells
Ongaro, M., Thouenon, R., Crespo, I., Dumez, A., Charmoy, M., Camacho, E. R., Morel, V. J., Cropp, D., Desponds, E., Zanette, G., et al. (2026) · The Journal of Experimental Medicine · doi:10.1084/jem.20252115 · Cited by 4
“We propose here a role for type I IFN, hallmark of chronic infections (Teijaro et al., 2013; Wilson et al., 2013), as repressor of IRF8 expression during chronic infection.”
Zhang, X., He, L., Zhang, R., Sun, H., Zhang, L., & Jin, C. (2024) · Zoonoses · doi:10.15212/zoonoses-2024-0016 · Cited by 5
Three modes of viral adaption by the heart
Griffiths, C. D., Shah, M., Shao, W., Borgman, C. A., & Janes, K. A. (2024) · Science Advances · doi:10.1126/sciadv.adp6303 · Cited by 4
Low, Z. X. B., Yong, S. J., AlRasheed, H. A., Al‐Subaie, M. F., Kaabi, N. A., Alfaresi, M. S., Albayat, H., Alotaibi, J., bshabshe, A. A. A. A., Alwashmi, A. S. S., et al. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111279 · Cited by 4
A myeloid IFN gamma response gene signature correlates with cancer prognosis
Zhang, Y., Khanniche, A., Li, Y., Wu, Z., Wang, H., Zhang, H., Li, X., Hu, L., & Kong, X. (2025) · Clinical and Translational Medicine · doi:10.1002/ctm2.70139 · Cited by 4
“3,4 11 For example, Joseph et al. 8 demonstrated that high levels of ISG expression in tumours, driven by chronic IFN-γ signalling, are associated with resistance to ICB, highlighting the context-dependent role of IFN-γ in cancer.”
Nash, W., Gillespie, A., & Brown, M. G. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00251 · Cited by 4
Chartrand, K., Lebel, M., Tarrab, E., Savard, P. E., Leclerc, D., & Lamarre, A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01885 · Cited by 4
Królik, M., Csepregi, L., Hartmann, F., Engetschwiler, C., & Flatz, L. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.01.047 · Cited by 4
Takaoka, A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820649-2.00115-7 · Cited by 4
Modulation of SIV and HIV DNA Vaccine Immunity by Fas-FasL Signaling
Yan, J., Zapata, J. C., Pauza, C. D., & Salvato, M. S. (2015) · Viruses · doi:10.3390/v7031429 · Cited by 4
“not significantly influenced, we speculate that cFLIP and FADD may modulate the innate immunity to fight the infection, as it has been reported that blocking type I interferon helps control chronic LCMV infection [52,53].”
BackgroundInactivation of Type I IFN Jak-STAT Pathway in EBV Latency
Wang, L. (2016) · Cancer Biology & Treatment · doi:10.24966/cbt-7546/100009 · Cited by 4
“At the early stage of infection, robust IFN-I response leads to a potent antiviral activity; meanwhile, it facilitates the establishment and maintenance of persistent infection by inducing the immune exhaustion program [20-21].”
BackgroundBhattacharya, B., Chattrerjee, S., Berland, R., Pichugin, A., Gao, Y., Connor, J. H., Ivanov, A., Yan, B.-S., Kobzik, L., & Kramnik, I. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/238873 · Cited by 4
“Numerous studies reveal a role of the type I interferon (IFN-I) pathway in the immunopathology caused by intracellular bacteria, including Mtb[67-70], chronic viral infections[71-73] and autoimmunity (reviewed in[74-76]).”
BackgroundAntigenic cancer persister cells survive direct T cell attackPreprint
Wang, M., Mauch, B. E., Williams, A. F., Barazande-Pour, T., Hoffmann, F. A., Harris, S. H., Lathrop, C. P., Turkal, C. E., Yung, B. S., Paw, M. H., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.14.643359 · Cited by 4
Reghupaty, S. C., Kanwal, S., Mendoza, R. G., Davis, E., Li, H., Lai, Z., Dozmorov, M. G., Faison, M. O., Siddiqui, R. A., & Sarkar, D. (2023) · Cancers · doi:10.3390/cancers15174283 · Cited by 3
“However, the detection of IFN-I-dependent ISG signature indicates that there is continuous production of IFN-Is [49,50].”
BackgroundShi, X., Su, S., Yang, Y., Meng, L., Yang, W. L., Qi, X., Xiang, X., Tang, Y., XueHui, C., Wang, H., et al. (2025) · Pathogens · doi:10.3390/pathogens14101026 · Cited by 3
“However, sustained or excessive IFN-I production and inflammatory responses may conversely inhibit T cell function [39].”
Targeting the pDC/IFN-I axis in HIV-1 immunotherapy
Su, L., Ahodantin, J., & Li, G. (2025) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000998 · Cited by 3
Hu, Z., Abdelrahman, H., Elwy, A., Kuang, F., Dhiman, S., Ali, S., Marson, M., Holnsteiner, L., Hamdan, T. A., Friebus‐Kardash, J., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1638403 · Cited by 4
“This aligns with earlier work showing that IFN-I licenses PD-L1 to prevent pathology in chronic LCMV (40).”
From host to population: Bridging the viral immuno-evolutionary gap
Jamaleddine, H., Grenfell, B. T., Graham, A. L., & Mandl, J. N. (2025) · Immunity · doi:10.1016/j.immuni.2025.12.001 · Cited by 3
The JAK/STAT Pathway in Cancer: From Molecular Mechanisms to Clinical Applications
Liao, Y., Wei, Q., Song, H., Zeng, H., Qi, C., Meng, Y., Zhang, Y., Zhang, Y., Li, W., Li, Y., et al. (2026) · MedComm – Oncology · doi:10.1002/mog2.70063 · Cited by 4
Soltero‐Rivera, M. M., Wanakumjorn, P., Chen, Y., Barnum, S. M., Charpentier, L. D. C., Arzi, B., Vapniarsky-Arzi, N., & Kol, A. (2026) · Scientific Reports · doi:10.1038/s41598-026-50658-0 · Cited by 3
Abdel–Haq, H. (2024) · Vaccines · doi:10.3390/vaccines12060583 · Cited by 3
Mizobuchi, H., Yamagishi, J., Sanjoba, C., & Goto, Y. (2025) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0012650 · Cited by 3
Identification of Candidate Predictors of Lupus Flare.
Crow, M. K., Olferiev, M., & Kirou, K. A. (2015) · Europe PMC (PubMed Central) · Cited by 4
Fernández-Sendin, M., Trani, C. A. D., Bella, Á., Vásquez, M., Ardaiz, N., Gomar, C., Arrizabalaga, L., Ciordia, S., Corrales, F. J., Aranda, F., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.620283 · Cited by 3
Jelinski, J., Kowatsch, M. M., Lafrance, M.-A., Berger, A., Pedersen, J., Azizi, H., Li, Y., Scholte, F. E. M., Gómez, A., Hollett, N. A., et al. (2023) · Emerging Microbes & Infections · doi:10.1080/22221751.2023.2251595 · Cited by 3
“which found that Type I IFN leads to T-cell exhaustion, and blockade of these cytokines can restore CD8 function [51,52].”
BackgroundAn Odyssey to Viral Pathogenesis
Oldstone, M. B. A. (2015) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-012615-044107 · Cited by 3
Li, J. Y. Y. (2013) · Journal of Bioanalysis & Biomedicine · doi:10.4172/1948-593x.1000e121 · Cited by 3
“Most recently, it has been shown that blocking type I IFN signaling by IFNAR antibody cures persistent LCMV infection, indicating that too much activation of the IFN signaling may contribute to chronic persistent viral infections [28,29].”
BackgroundThe Different Modes of Resistance to AIDS
Chakrabarti, L. A. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-404734-1.00015-2 · Cited by 3
Liu, R., Americo, J. L., Earl, P. L., Villani, J., Cotter, C. A., & Moss, B. (2022) · mBio · doi:10.1128/mbio.00102-22 · Cited by 3
“An anti-IFNAR1 blocking MAb (21) was administered to unin-”
MethodTransition of T Cells from Effector to Memory Phase
Schauder, D., & Cui, W. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-374279-7.08013-9 · Cited by 4
STAT1-dependent tolerance of intestinal viral infectionPreprint
Filyk, H. A., Sharon, A. J., Fonseca, N. M., Simister, R. L., Yuen, W., Hardman, B. K., Robinson, H. G., Seo, J. H., Rocha‐Pereira, J., Welch, I. D., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.02.13.936252 · Cited by 3
ISG15 drives immune pathology and respiratory failure during viral infectionPreprint
Shaabani, N., Žák, J., Johnson, J. L., Huang, Z., Nguyen, N., Lazar, D. C., Vartabedian, V. F., Honke, N., Prinz, M., Knobeloch, K., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.04.13.039321 · Cited by 3
“Despite the central role of IFN-I in promoting an antiviral state, deleterious consequences of IFN-I signaling during viral infection have been reported (Ng et al., 2015; Shaabani et al., 2018; Teijaro et al., 2013; Wilson et al., 2013).”
Background
Metadata
- Authors
- Wilson, E. B., Yamada, D. H., Elsaesser, H., Herskovitz, J., Deng, J., Cheng, G., Aronow, B. J., Karp, C. L., & Brooks, D. G.
- Affiliations
- University of California, Los Angeles (US)
- Cincinnati Children's Hospital Medical Center (US)
- Corresponding author
- Brooks, David G.
- ORCID
- Venue
- Science
- Published
- 2013-04-12
- Volume
- 340
- Issue
- 6129
- Pages
- 202-207
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC3704950
- OpenAlex
- W2049868800
- Cited by
- 709
- References
- 29
- Citations by year
- 2026: 26 · 2025: 37 · 2024: 34 · 2023: 35 · 2022: 35 · 2021: 48 · 2020: 50 · 2019: 50 · 2018: 58 · 2017: 72 · 2016: 87 · 2015: 72 · 2014: 70 · 2013: 34
- FWCI
- 48.52
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (UL1TR000077)
- National Heart, Lung, and Blood Institute (R01HL108949, HL108949)
- National Institute of Allergy and Infectious Diseases (AI060567, T32AI060567, U01AI082975, R01AI085043, AI082975, R01AI056154, AI085043, R01AI047868, P30AI028697)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (P50AR063020)
- National Center for Advancing Translational Sciences
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
- Keywords
- type I interferon signaling, chronic infection, lymphocytic choriomeningitis virus, viral persistence, immune activation, immunosuppression, CD4+ T cells, interferon-gamma, antiviral immunity, viral clearance
- MeSH terms
- Animals, Antibodies, Arenaviridae Infections, Dendritic Cells, Immune Tolerance, Interferon Type I, Interferon-gamma, Lymphocytic choriomeningitis virus, Virus Replication, Signal Transduction, CD4-Positive T-Lymphocytes, Cytokines, Interleukin-10, Oligonucleotide Array Sequence Analysis, Gene Expression Profiling, Mice, Receptor, Interferon alpha-beta, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.